Ultivue, Inc.

Ultivue, Inc. is a biotechnology company focused on developing advanced biomarker assays and image informatics solutions, enhancing research capabilities in precision medicine and tissue analysis. Founded in 2015 in Cambridge, US, Ultivue specializes in innovative biomarker analysis technologies. The company has undergone strategic advancements but operates independently without known subsidiaries.

Key founders include David Walt, Peng Yin, and Ralf Jungmann, while Jacques Corriveau serves as CEO. Ultivue has raised a total of USD 12. 00 mn through its latest funding round, a Series A, which was completed in 2024 with contributions from prominent investors such as ARCH Venture Partners and Northpond Ventures. The company’s current valuation stands at USD 33.

82 mn. Ultivue specializes in advanced biomarker assays and image informatics solutions, prominently featuring its flagship InSituPlex® technology. This proprietary platform enables researchers to conduct multiplex biomarker analysis with high sensitivity and specificity through the use of DNA barcoded antibodies that facilitate the visualization of multiple antigens in tissue samples. Ultivue's OmniVUE™ panels and U-VUE® custom biomarkers are integral for scientists involved in precision medicine research, supporting a range of applications from cancer therapy development to tissue microenvironment studies.

The company's products are utilized by academic institutions, biotech firms, and pharmaceutical companies primarily in North America and Europe, fostering innovative approaches in translational research. Through a consultative service model, Ultivue provides tailored solutions to meet the unique needs of its diverse client base. Ultivue operates on a transactional model that encompasses both direct sales and partnerships within the life sciences sector. The company offers pre-optimized biomarker panels and customizable assay development services, which are typically sold as ready-to-use kits to research institutions and laboratories.

Partnerships with leading biotech firms enhance the distribution of Ultivue's products, facilitating a streamlined path from research to application. The modular nature of the InSituPlex® technology, available in various panel configurations, allows clients to select products based on their specific research requirements. The revenue structure is supported by a strong emphasis on high-throughput capabilities and rapid delivery timelines, ensuring that clients can efficiently integrate Ultivue's offerings into their research workflows. In October 2024, Ultivue, Inc.

merged into Vizgen, Inc. , which will enable the combined entity to offer unified solutions in spatial multi-omics and drive future technology breakthroughs. This merger aligns with Ultivue's strategy to enhance its product offerings and expand its market reach. The recent funding will support these initiatives, allowing for the development and launch of new products designed to cater to broader applications in research.

The company aims to solidify its presence in existing markets while exploring expansions into new geographic regions as it continues to innovate in biomarker technologies.